Plain-English translation of NCT06922604 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether , a new type of immunotherapy medication, combined with (another immune-boosting drug), can safely and effectively treat lymphoma affecting the brain. The study is designed to see if this medication combination works better than current treatments for patients whose cancer has spread to the brain or originated there, especially those who have already tried other standard therapies.
Brain lymphoma is difficult to treat because most cancer medications cannot easily reach the brain. Researchers believe this new treatment approach might work better because it uses the body's immune system to fight the cancer. This trial will help doctors understand if this medication can cross the protective barrier around the brain and work without causing serious side effects.
If accepted, you would receive two medications given through an IV (intravenous line): on the first day and on days 8 and 15 of your first cycle, then on day 1 of each subsequent cycle. Treatment cycles last 21 days, and you could receive up to 12 cycles (about 9 months) depending on how well the medication works. Throughout the study, you would have regular MRI scans of your brain, blood tests, and possibly spinal taps to check if the cancer is responding. You would also be monitored closely for side effects at follow-up visits for up to 2 years after treatment ends.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States